---
document_datetime: 2025-09-17 10:24:10
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mylotarg-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mylotarg-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.2140927
conversion_datetime: 2025-12-18 21:33:41.062387
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Mylotarg

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber                     | Scope                                                                       | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------------------------|-----------------------------------------------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| VariationtypeIA_IN/ EMA/VR/0000278463 | B.II.b.2.cReplacementor addition of a manufacturerresponsibleforimportation | 11/09/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC(Summary of Product Characteristics),Annex II, Labelling, PL (Package Leaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | and/or batch release - B.11.b.2.c.1 Not includingbatchcontrol/testing-Accepted                                                                                                                                                                                                                                                                                                                                                                                                               |            |     | PL   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IA / EMA/VR/0000237706 | A.ADMINISTRATIVE CHANGES -A.4 Change in the name and/or address of: a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagent orintermediate usedinthemanufactureof the active substance(where specified in the technical dossier)where noPh.Eur.Certificate of Suitabilityispartof theapproveddossier;or amanufacturerofanovelexcipient(where specified in the technical dossier) - Accepted | 06/03/2025 | N/A |      |